Valeant Pharmaceuticals agreed to purchase Solta Medical’s shares at $2.92 per cash share. The deal is expected to close in the first quarter of 2014.
Solta Medical develops energy-based aesthetic medical device systems. Its total revenue in 2012 was $145 million, according to the report.
More Articles on Supply Chain Transactions:
CVS, Cardinal Health Enter Generic Drug Joint Venture
Northeast Purchasing Coalition Moves to Online Contracting
Myco Medical, Novation Enter Private-Label Contract
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
